Match!
Richard E. Pratley
Sanford-Burnham Institute for Medical Research
214Publications
64H-index
22.4kCitations
Publications 217
Newest
Source
Source
Incretin hormone dysregulation contributes to reduced insulin secretion and hyperglycemia in patients with Type 2 Diabetes Mellitus (T2DM). Resistance to glucose dependent insulinotropic polypeptide (GIP) action may occur through desensitization or down-regulation of β-cell GIP receptors (GIP-R). Studies in rodents and cell lines show GIP-R expression can be regulated through peroxisome proliferation-activated receptor-γ (PPARγ) response elements (PPRE). Whether this occurs in humans is unknown....
Source
#1Lawrence A. LeiterH-Index: 71
#2Stephen C. BainH-Index: 25
Last.Subodh VermaH-Index: 70
view all 10 authors...
Source
#1Robyn L. HouldenH-Index: 16
#2Ofri MosenzonH-Index: 21
Last.Cyrus V DesouzaH-Index: 18
view all 10 authors...
Source
#1Ronald GoldenbergH-Index: 14
#2Richard E. PratleyH-Index: 64
Last.Adie ViljoenH-Index: 17
view all 9 authors...
Source
#1Erin S. LeBlancH-Index: 15
#2Richard E. PratleyH-Index: 64
Last.Anastassios G. PittasH-Index: 41
view all 26 authors...
In the article cited above, there were some differences in means and proportions of a few variables between the published data and …
Source
Abstract Background Observational studies support an association between a low blood 25-hydroxyvitamin D level and the risk of type 2 diabetes. However, whether vitamin D supplementation lowers the...
15 CitationsSource
#1Cees J. TackH-Index: 37
#2Stephan JacobH-Index: 35
Last.Julio RosenstockH-Index: 113
view all 13 authors...
Source
#1Richard E. PratleyH-Index: 64
#2Vanita R. ArodaH-Index: 20
Last.Adie ViljoenH-Index: 17
view all 8 authors...
Semaglutide and dulaglutide are glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes (T2D). In SUSTAIN 7, an international, open-label, parallel group trial, adults with inadequately controlled T2D were randomized (1:1:1:1) to once-weekly subcutaneous semaglutide or dulaglutide at low (0.5 vs. 0.75 mg) or high (1.0 vs. 1.5 mg) doses. Semaglutide provided superior glycemic control and reductions in body weight at both low and high doses. To study doses available in clini...
Source
12345678910